Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Pegunigalsidase alfa

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chiesi Global Rare Diseases Receives Canada Approval of Elfabrio
    Chiesi Global Rare Diseases Receives Canada Approval of Elfabrio

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206235/0/en/Chiesi-Global-Rare-Diseases-Announces-Health-Canada-Approval-of-Elfabrio-pegunigalsidase-alfa-for-Fabry-Disease.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Chiesi, Protalix Seek EMA Re-Exam for Elfabrio 4-Week Dosing
    Chiesi, Protalix Seek EMA Re-Exam for Elfabrio 4-Week Dosing

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179856/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Seek-Re-examination-from-the-EMA-for-the-Negative-Opinion-for-Elfabrio-pegunigalsidase-alfa-Alternative-Dosing-Regimen-of-E.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

    05 Sep 2023

    // PM LIVE

    https://www.pmlive.com/pharma_news/nice_recommends_chiesis_elfabrio_for_adults_with_fabry_disease_1497865

    PM LIVE
    05 Sep 2023
    Share Share
    Chiesi Farmaceutici's Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe
    Chiesi Farmaceutici's Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe

    25 May 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/elfabrio-epar-medicine-overview_en.pdf

    EMA
    25 May 2023
    Share Share
    Chiesi's Biologic Elfabrio (Pegunigalsidase alfa) Receives Approval in the U.S.
    Chiesi's Biologic Elfabrio (Pegunigalsidase alfa) Receives Approval in the U.S.

    09 May 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761161

    FDA
    09 May 2023
    Share Share
    Protalix & Chiesi gain positive opinion for pegunigalsidase alfa
    Protalix & Chiesi gain positive opinion for pegunigalsidase alfa

    06 Mar 2023

    // John Pinching PHARMATIMES

    https://www.pharmatimes.com/news/protalix_and_chiesi_gain_positive_opinion_for_pegunigalsidase_alfa_1488829

    John Pinching PHARMATIMES
    06 Mar 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.